BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37752541)

  • 1. [Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer].
    Liu Y; Xiong L; Cai R; Chen Y; Ye J; Shen B; Zhou G
    Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):615-620. PubMed ID: 37752541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer.
    Xiaoxu D; Min X; Chengcheng C
    BMC Pulm Med; 2024 Mar; 24(1):155. PubMed ID: 38532454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.
    Mei SQ; Liu JQ; Huang ZJ; Luo WC; Peng YL; Chen ZH; Deng Y; Xu CR; Zhou Q
    Thorac Cancer; 2024 May; 15(14):1119-1131. PubMed ID: 38558529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
    Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
    Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study.
    Fukuhara M; Muto S; Inomata S; Yamaguchi H; Mine H; Takagi H; Ozaki Y; Watanabe M; Inoue T; Yamaura T; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Shio Y; Suzuki H
    Cancer Immunol Immunother; 2022 May; 71(5):1129-1137. PubMed ID: 34596720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
    Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
    Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer.
    Rakaee M; Kilvaer TK; Jamaly S; Berg T; Paulsen EE; Berglund M; Richardsen E; Andersen S; Al-Saad S; Poehl M; Pezzella F; Kwiatkowski DJ; Bremnes RM; Busund LR; Donnem T
    Br J Cancer; 2021 May; 124(10):1680-1689. PubMed ID: 33723388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tertiary Lymphoid Structures, Immune Response, and Prognostic Relevance in Non-Small Cell Lung Cancer.
    Giatromanolaki A; Chatzipantelis P; Contrafouris CA; Koukourakis MI
    Cancer Invest; 2023 Jan; 41(1):48-57. PubMed ID: 36239379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.
    He M; He Q; Cai X; Liu J; Deng H; Li F; Zhong R; Lu Y; Peng H; Wu X; Chen Z; Lao S; Li C; Li J; He J; Liang W
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
    Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
    EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
    Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
    Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research Progress of Immunotherapy and Prognostic Markers in Small Cell Lung Cancer].
    Wang Q; Peng W; Jiang M; Wu L
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):182-188. PubMed ID: 32102135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
    Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
    Front Immunol; 2021; 12():629519. PubMed ID: 33746966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies.
    N J; J T; Sl N; Gt B
    Oncoimmunology; 2021 Mar; 10(1):1900508. PubMed ID: 33854820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma.
    Yao Y; Xuan H; Wang J; Gong L; Gao W
    Tumori; 2023 Oct; 109(5):466-480. PubMed ID: 37249074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Associated Tertiary Lymphoid Structures: A Cancer Biomarker and a Target for Next-generation Immunotherapy.
    Dieu-Nosjean MC
    Adv Exp Med Biol; 2021; 1329():51-68. PubMed ID: 34664233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tertiary lymphoid structures and cytokines interconnections: The implication in cancer immunotherapy.
    Li H; Ding JY; Zhang MJ; Yu HJ; Sun ZJ
    Cancer Lett; 2023 Aug; 568():216293. PubMed ID: 37392991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tertiary lymphoid structures in the era of cancer immunotherapy.
    Sautès-Fridman C; Petitprez F; Calderaro J; Fridman WH
    Nat Rev Cancer; 2019 Jun; 19(6):307-325. PubMed ID: 31092904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.
    Filderman JN; Appleman M; Chelvanambi M; Taylor JL; Storkus WJ
    Front Immunol; 2021; 12():690105. PubMed ID: 34054879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.